Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Ibrahim Yakoub‐Agha, Marion Subklewe et al.|Blood|2023Cited by 330
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeGeoffrey L. Uy, John F. DiPersio, Gerwin Huls et al.|Blood|2017Cited by 62
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Geoffrey L. Uy, John F. DiPersio, Michael P. Rettig et al.|Blood|2018Cited by 40
A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.Norbert Vey, John F. DiPersio, Jan Davidson‐Moncada et al.|Journal of Clinical Oncology|2017Cited by 8